Biomerica (NASDAQ:BMRA) Earns Buy Rating from Analysts at B. Riley

Analysts at B. Riley initiated coverage on shares of Biomerica (NASDAQ:BMRA) in a research note issued on Thursday, January 4th, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $7.50 price target on the stock. B. Riley’s target price would indicate a potential upside of 51.52% from the company’s previous close.

Separately, ValuEngine raised Biomerica from a “sell” rating to a “hold” rating in a research report on Saturday, November 4th.

Shares of Biomerica (NASDAQ:BMRA) opened at $4.95 on Thursday. Biomerica has a twelve month low of $1.93 and a twelve month high of $9.32.

Biomerica (NASDAQ:BMRA) last released its earnings results on Monday, October 16th. The company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $1.52 million. Biomerica had a negative return on equity of 22.82% and a negative net margin of 18.19%. equities research analysts anticipate that Biomerica will post -0.16 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Biomerica (NASDAQ:BMRA) Earns Buy Rating from Analysts at B. Riley” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at

About Biomerica

Biomerica, Inc is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores).

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.

Leave a Reply